The discoveries of tumor-driver genes such as epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), mesenchymal-epithelial transition (MET), and c-ros oncogene 1 (ROS1) in NSCLC have recommended TKIs as the first-line option for patients with advanced stage disease. The gene discussed is ALK; the disease is non-small cell lung carcinoma.